Ocular graft-versus-host disease: A review

Survey of Ophthalmology

Volumn 58, Issue 3, 2013, Pages 233-251

  Shikari, Hasanain ^a,b,c   Antin, Joseph H ^c,d,e   Dana, Reza ^a,b,c  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Allogeneic bone marrow transplantation; Dry eye disease; Graft versus host disease; Hematopoietic stem cells; Ocular GVHD; Ocular surface disease

Indexed keywords

ALEMTUZUMAB; ARTIFICIAL TEAR; CYCLOSPORIN; IMATINIB; INTERLEUKIN 2; PILOCARPINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRANILAST; TUMOR NECROSIS FACTOR INHIBITOR;

ACUTE GRAFT VERSUS HOST DISEASE; ANAPHYLAXIS; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELL ACTIVATION; CHILL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CONTACT LENS; CORD SERUM; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRY EYE; FEVER; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS SICCA; MANAGED CARE; NONHUMAN; OCULAR SURFACE DISEASE; PATHOPHYSIOLOGY; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; PUVA; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; SYMPTOM ASSESSMENT; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TREATMENT PLANNING;

BONE MARROW TRANSPLANTATION; EYE DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84876416509     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2012.08.004     Document Type: Review

References (180)

1. Agomo E.U., Tan A., Champlin R., et al. Role of ocular surface disease index (OSDI) in chronic ocular graft vs. host disease (OGVHD). Invest Ophthalmol Vis Sci 2008, 49:2369.
2. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
3. Anderson N.G., Regillo C. Ocular manifestations of graft versus host disease. Curr Opin Ophthalmol 2004, 15:503-507.
4. Antin J.H., Ferrara J.L. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992, 80:2964-2968.
5. Aoki S., Mizote H., Minamoto A., et al. Systemic FK506 improved tear secretion in dry eye associated with chronic graft versus host disease. Br J Ophthalmol 2005, 89:243-244.
6. Arocker-Mettinger E., Skorpik F., Grabner G., et al. Manifestations of graft-versus-host disease following allogenic bone marrow transplantation. Eur J Ophthalmol 1991, 1:28-32.
7. Arora M., Klein J.P., Weisdorf D.J., et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011, 117:6714-6720.
8. Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007, 137:87-98.
9. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
10. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
11. Balaram M., Rashid S., Dana R. Chronic ocular surface disease after allogeneic bone marrow transplantation. Ocul Surf 2005, 3:203-211.
12. Balaram M., Schaumberg D.A., Dana M.R. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 2001, 131:30-36.
13. Barber L.D., Pflugfelder S.C., Tauber J., et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005, 112:1790-1794.
14. Barr M.L., Meiser B.M., Eisen H.J., et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998, 339:1744-1751.
15. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344:175-181.
16. Bernauer W., Gratwohl A., Keller A., et al. Microvasculopathy in the ocular fundus after bone marrow transplantation. Ann Intern Med 1991, 115:925-930.
17. Bhan A.K., Mihm M.C., Dvorak H.F. T cell subsets in allograft rejection. In situ characterization of T cell subsets in human skin allografts by the use of monoclonal antibodies. J Immunol 1982, 129:1578-1583.
18. Blaise D., Kuentz M., Fortanier C., et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000, 18:537-546.
19. Bolwell B., Sobecks R., Pohlman B., et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004, 34:621-625.
20. Bray L.C., Carey P.J., Proctor S.J. Ocular complications of bone marrow transplantation. Br J Ophthalmol 1991, 75:611-614.
21. Brown G.R., Lee E., Thiele D.L. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x bm12)F1 mice. J Immunol 2002, 168:3065-3071.
22. Jea Chang-Strepka Videokeratoscopic indices in chronic ocular graft versus host disease (OGVHD). Invest Ophthalmol Vis Sci 2009, 50S:2610.
23. Choi S.W., Kitko C.L., Braun T., et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008, 112:1539-1542.
24. Cohen J.L., Boyer O. The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. Curr Opin Immunol 2006, 18:580-585.
25. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996, 88:3230-3239.
26. Corre E., Carmagnat M., Busson M., et al. Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections. Haematologica 2010, 95:1025-1029.
27. Coskuncan N.M., Jabs D.A., Dunn J.P., et al. The eye in bone marrow transplantation. VI. Retinal complications. Arch Ophthalmol 1994, 112:372-379.
28. Couriel D., Caldera H., Champlin R., et al. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004, 101:1936-1946.
29. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006, 12:375-396.
30. Couriel D., Hosing C., Saliba R., et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?. Biol Blood Marrow Transplant 2006, 12(1 Suppl 2):37-40.
31. Cragg L., Blazar B.R., Defor T., et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000, 6(4A):441-447.
32. Cutler C., Giri S., Jeyapalan S., et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001, 19:3685-3691.
33. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
34. Dastjerdi M.H., Hamrah P., Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 2009, 28:1091-1096.
35. Delgado J., Thomson K., Russell N., et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006, 107:1724-1730.
36. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004, 104:1550-1558.
37. Dietrich-Ntoukas T., Cursiefen C., Westekemper H., et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: Report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in Chronic GVHD. Cornea 2012, 31:299-310.
38. Doughty M.J., Glavin S. Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol Opt 2009, 29:573-583.
39. Dustin M.L. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 2001, 21:258-263.
40. Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007, 13:1461-1468.
41. Fang B., Li N., Song Y., et al. Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia. Pediatr Transplant 2009, 13:499-502.
42. Ferrara J.L., Levine J.E., Reddy P., et al. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
43. Ferrara J.L.M. Graft-versus-Host Disease 1999, W. B. Saunders Company, Philadelphia, PA.
44. Ferrara J.L., Antin J.H. The pathophysiology of graft-versus-host disease. Thomas' Hematopoietic Cell Transplantation 1999, 305-315. Wiley-Blackwell, Oxford, UK. S.J. Forman (Ed.).
45. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
46. Franklin R.M., Kenyon K.R., Tutschka P.J., et al. Ocular manifestations of graft-vs-host disease. Ophthalmology 1983, 90:4-13.
47. Gale R.P., Bortin M.M., van Bekkum D.W., et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987, 67:397-406.
48. Glas A.M., van Montfort E.H., Storek J., et al. B-cell-autonomous somatic mutation deficit following bone marrow transplant. Blood 2000, 96:1064-1069.
49. Gloor B., Gratwohl A., Hahn H., et al. Multiple cotton wool spots following bone marrow transplantation for treatment of acute lymphatic leukaemia. Br J Ophthalmol 1985, 69:320-325.
50. Gluckman E., Rocha V., Boyer-Chammard A., et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997, 337:373-381.
51. Gratwohl A.A., Moutsopoulos H.M., Chused T.M., et al. Sjogren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med 1977, 87:703-706.
52. Greinix H.T., Knobler R.M., Worel N., et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006, 91:405-408.
53. Greinix H.T., Pohlreich D., Kouba M., et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008, 14:208-219.
54. Hahn T., McCarthy P.L., Zhang M.J., et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008, 26:5728-5734.
55. Heath J.D., Acheson J.F., Schulenburg W.E. Penetrating keratoplasty in severe ocular graft versus host disease. Br J Ophthalmol 1993, 77:525-526.
56. Heldal D., Tjonnfjord G., Brinch L., et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000, 25:1129-1136.
57. Higman M.A., Vogelsang G.B. Chronic graft versus host disease. Br J Haematol 2004, 125:435-454.
58. Hill G.R., Crawford J.M., Cooke K.R. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997, 90:3204-3213.
59. Hill G.R., Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000, 95:2754-2759.
60. Hill G.R., Teshima T., Rebel V.I., et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol 2000, 164:656-663.
61. Hirst L.W., Jabs D.A., Tutschka P.J., et al. The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol 1983, 101:580-584.
62. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001, 98:3192-3204.
63. Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 2007, 20:281-294.
64. Inamoto Y., Chai X., Kurland B.F., et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology 2012, 119:487-493.
65. Jabs D.A., Hirst L.W., Green W.R., et al. The eye in bone marrow transplantation. II. Histopathology. Arch Ophthalmol 1983, 101:585-590.
66. Jabs D.A., Wingard J., Green W.R., et al. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol 1989, 107:1343-1348.
67. Jack M.K., Jack G.M., Sale G.E., et al. Ocular manifestations of graft-v-host disease. Arch Ophthalmol 1983, 101:1080-1084.
68. Jacobs D.S., Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea 2007, 26:1195-1199.
69. Jagasia M., Arora M., Flowers M., et al. Risk-factors for acute graft-versus-host disease and survival after hematopoietic cell transplantation from siblings and unrelated donors: An analysis of the CIBMTR. Blood (ASH Annu Meet Abstracts) 2010, 116:897.
70. Janin A., Facon T., Castier P., et al. Pseudomembranous conjunctivitis following bone marrow transplantation: immunopathological and ultrastructural study of one case. Hum Pathol 1996, 27:307-309.
71. Kenyon K.R., Tseng S.C. Limbal autograft transplantation for ocular surface disorders. Ophthalmology 1989, 96:709-722. discussion 722-3.
72. Kiang E., Tesavibul N., Yee R., et al. The use of topical cyclosporin A in ocular graft-versus-host-disease. Bone Marrow Transplant 1998, 22:147-151.
73. Kim H., Csaky K.G., Gilger B.C., et al. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci. 2005, 46:655-662.
74. Kim S.K. Update on ocular graft versus host disease. Curr Opin Ophthalmol 2006, 17:344-348.
75. Kim S.K., Melton J., Couriel D., et al. Surgical management of Ocular Graft vs. Host disease. Invest Ophthalmol Vis Sci. 2008, 49:819. (Suppl).
76. Kim S.K., Couriel D., Ghosh S., et al. Ocular graft vs. host disease experience from MD Anderson Cancer Center: Newly described clinical spectrum and new approach to the management of stage III and IV ocular GVHD. Biol Blood Marrow Transplant 2006, 12:49-50.
77. Kino T., Hatanaka H., Miyata S., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987, 40:1256-1265.
78. Koreth J., Matsuoka K., Kim H.T., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011, 365:2055-2066.
79. Kroger N., Zabelina T., Kruger W., et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002, 29:683-689.
80. Kurtzberg J., Laughlin M., Graham M.L., et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166.
81. Lawley T.J., Peck G.L., Moutsopoulos H.M., et al. Scleroderma, Sjogren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med 1977, 87:707-709.
82. Lelli G.J., Musch D.C., Gupta A., et al. Ophthalmic cyclosporine use in ocular GVHD. Cornea 2006, 25:635-638.
83. Lemp M.A. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J 1995, 21:221-232.
84. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008, 111:2470-2475.
85. Levine J.E., Uberti J.P., Ayash L., et al. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 2003, 9:189-197.
86. Lin M.T., Storer B., Martin P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003, 349:2201-2210.
87. Loiseau P., Busson M., Balere M.L., et al. HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant 2007, 13:965-974.
88. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
89. Magro L., Catteau B., Coiteux V., et al. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008, 42:757-760.
90. Malek T.R., Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004, 4:665-674.
91. Malta J.B., Soong H.K., Shtein R.M., et al. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea 2010, 29:1392-1396.
92. Management and Therapy Subcommittee of the International Dry Eye WorkShop. Management and therapy of dry eye disease: Report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007, 5:163-178.
93. Maris M., Storb R. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases. Immunol Res 2003, 28:13-24.
94. Marr K.A., Carter R.A., Boeckh M., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100:4358-4366.
95. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990, 76:1464-1472.
96. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991, 77:1821-1828.
97. Martin P.J., Storer B.E., Rowley S.D., et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009, 113:5074-5082.
98. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006, 12:491-505.
99. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836-846.
100. Marty F.M., Lee S.J., Fahey M.M., et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003, 102:2768-2776.
101. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
102. Maury S., Mary J.Y., Rabian C., et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol 2001, 115:630-641.
103. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007, 5:108-152. Diagnostic Methodology Subcommittee.
104. Mielcarek M., Martin P.J., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
105. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
106. Miklos D.B., Kim H.T., Zorn E., et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004, 103:353-359.
107. Miller J.S., Warren E.H., van den Brink M.R., et al. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-tumor/leukemia reaction. Biol Blood Marrow Transplant 2010, 16:565-586.
108. Milosevic S., Bachnick B., Karim K., et al. Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation. Transplantation 2010, 90:1030-1035.
109. Mottet C., Uhlig H.H., Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003, 170:3939-3943.
110. Murphy P.T., Sivakumaran M., Fahy G., et al. Successful use of topical retinoic acid in severe dry eye due to chronic graft-versus-host disease. Bone Marrow Transplant 1996, 18:641-642.
111. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
112. Nelson B.H. IL-2, regulatory T cells, and tolerance. J Immunol 2004, 172:3983-3988.
113. Ochs L.A., Miller W.J., Filipovich A.H., et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant 1994, 13:455-460.
114. Ogawa Y., Dogru M., Uchino M., et al. Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. Bone Marrow Transplant 2010, 45:565-569.
115. Ogawa Y., Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea 2003, 22(7 Suppl):S19-S27.
116. Ogawa Y., Okamoto S., Kuwana M., et al. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea 2001, 20:430-434.
117. Ogawa Y., Okamoto S., Mori T., et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003, 31:579-583.
118. Ogawa Y., Yamazaki K., Kuwana M., et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci 2001, 42:111-119.
119. Okanobo A., Chauhan S.K., Dastjerdi M.H., et al. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol 2012, 154(1):63-71.
120. Olivieri A., Locatelli F., Zecca M., et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009, 114:709-718.
121. Pachigolla G., Prasher P., Di Pascuale M.A., et al. Evaluation of the role of ProKera in the management of ocular surface and orbital disorders. Eye Contact Lens 2009, 35:172-175.
122. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006, 12:252-266.
123. Perez R.L., Perez-Simon J.A., Caballero-Velazquez T., et al. Limbus damage in ocular graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17:270-273.
124. Perez-Simon J.A., Diez-Campelo M., Martino R., et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005, 130:394-403.
125. Peris-Martinez C., Menezo J.L., Diaz-Llopis M., et al. Multilayer amniotic membrane transplantation in severe ocular graft versus host disease. Eur J Ophthalmol 2001, 11:183-186.
126. Pidala J., Anasetti C., Kharfan-Dabaja M.A., et al. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:1415-1421.
127. Piguet P.F., Grau G.E., Allet B., et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987, 166:1280-1289.
128. Platzbecker U., Ehninger G., Bornhauser M. Allogeneic transplantation of CD34+ selected hematopoietic cells-clinical problems and current challenges. Leuk Lymphoma 2004, 45:447-453.
129. Powles R., Mehta J., Kulkarni S., et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000, 355:1231-1237.
130. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9:505-511.
131. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
132. Reddy P., Ferrara J.L. Immunobiology of acute graft-versus-host disease. Blood Rev 2003, 17:187-194.
133. Reddy P., Teshima T., Kukuruga M., et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001, 194:1433-1440.
134. Remberger M., Mattsson J., Ringden O. Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. Pediatr Transplant 2001, 5:285-292.
135. Robinson M.R., Lee S.S., Rubin B.I., et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant 2004, 33:1031-1035.
136. Rocha E.M., Pelegrino F.S., de Paiva C.S., et al. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant 2000, 25:1101-1103.
137. Russo P.A., Bouchard C.S., Galasso J.M. Extended-wear silicone hydrogel soft contact lenses in the management of moderate to severe dry eye signs and symptoms secondary to graft-versus-host disease. Eye Contact Lens 2007, 33:144-147.
138. Saito T., Shinagawa K., Takenaka K., et al. Ocular manifestation of acute graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Int J Hematol 2002, 75:332-334.
139. Sales C.S., Johnston L.J., Ta C.N. Long-term clinical course of dry eye in patients with chronic graft-versus-host disease referred for eye examination. Cornea 2011, 30:143-149.
140. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007, 13:6107-6114.
141. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009, 113:3865-3874.
142. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood 2011, 117:2275-2283.
143. Schmitz N., Bacigalupo A., Hasenclever D., et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998, 21:995-1003.
144. Schornack M.M., Baratz K.H., Patel S.V., et al. Jupiter scleral lenses in the management of chronic graft versus host disease. Eye Contact Lens 2008, 34:302-305.
145. Schultz K.R., Miklos D.B., Fowler D., et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant 2006, 12:126-137.
146. Shimabukuro-Vornhagen A., Hallek M.J., Storb R.F., et al. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009, 114:4919-4927.
147. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
148. Shulman H.M., Kleiner D., Lee S.J., et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006, 12:31-47.
149. Smith V.A., Cook S.D. Doxycycline-a role in ocular surface repair. Br J Ophthalmol 2004, 88:619-625.
150. Smith V.A., Khan-Lim D., Anderson L., et al. Does orally administered doxycycline reach the tear film?. Br J Ophthalmol 2008, 92:856-859.
151. Soiffer R. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant 2008, 42(Suppl 1):S66-S69.
152. Applebaum F.R., Forman S.J., Negrin R.S., Blume K.G. T-Cell Depletion to Prevent Graft-vs-Host Disease. Thomas' Hematopietic Cell Transplantation: Stem Cell Transplantation 2009, 1275-1286. Wiley-Blackwell, Oxford, UK. 4th ed. R.J. Soiffer (Ed.).
153. Solomon A., Dursun D., Liu Z., et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001, 42:2283-2292.
154. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
155. Stevenson D., Tauber J., Reis B.L. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000, 107:967-974.
156. Storek J., Espino G., Dawson M.A., et al. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 2000, 96:3290-3293.
157. Sullivan K.M. Graft-versus-host disease. Thomas' Hematopoietic Cell Transplantation 1999, 515-536. Wiley-Blackwell, Oxford, UK. S.J. Forman (Ed.).
158. Takahide K., Parker P.M., Wu M., et al. Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:1016-1021.
159. Tang Q., Henriksen K.J., Bi M., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004, 199:1455-1465.
160. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002, 8:575-581.
161. Thien M., Phan T.G., Gardam S., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
162. Thomas E., Storb R., Clift R.A., et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975, 292:832-843.
163. Tichelli A., Duell T., Weiss M., et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects. Bone Marrow Transplant 1996, 17:1105-1111.
164. Townley J.R., Dana R., Jacobs D.S. Keratoconjunctivitis sicca manifestations in ocular graft versus host disease: pathogenesis, presentation, prevention, and treatment. Semin Ophthalmol 2011, 26:251-260.
165. Vigorito A.C., Azevedo W.M., Marques J.F., et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998, 22:1145-1151.
166. Vogelsang G.B. Acute and chronic graft-versus-host disease. Curr Opin Oncol 1993, 5:276-281.
167. Vogelsang G.B., Lee L., Bensen-Kennedy D.M. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003, 54:29-52.
168. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
169. Wagner J.E., Thompson J.S., Carter S.L., et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005, 366:733-741.
170. Welniak L.A., Blazar B.R., Murphy W.J. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007, 25:139-170.
171. West R.H., Szer J., Pedersen J.S. Ocular surface and lacrimal disturbances in chronic graft-versus-host disease: the role of conjunctival biopsy. Aust NZ J Ophthalmol 1991, 19:187-191.
172. Westeneng A.C., Hettinga Y., Lokhorst H., et al. Ocular graft-versus-host disease after allogeneic stem cell transplantation. Cornea 2010, 29:758-763.
173. Wiznia R.A., Rose A., Levy A.L. Occlusive microvascular retinopathy with optic disc and retinal neovascularization in acute lymphocytic leukemia. Retina 1994, 14:253-255.
174. Wolff D., Schleuning M., von Harsdorf S., et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17:1-17.
175. Xun C.Q., Thompson J.S., Jennings C.D., et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994, 83:2360-2367.
176. Yaguchi S., Ogawa Y., Kamoi M., et al. Surgical management of lacrimal punctal cauterization in chronic GVHD-related dry eye with recurrent punctal plug extrusion. Bone Marrow Transplant 2012, 47(11):1465-1469.
177. Yang Y.G., Dey B.R., Sergio J.J., et al. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 1998, 102:2126-2135.
178. Yoon K.C., Jeong I.Y., Im S.K., et al. Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease. Bone Marrow Transplant 2007, 39:231-235.
179. Zaja F., Bacigalupo A., Patriarca F., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007, 40:273-277.
180. Zorn E., Miklos D.B., Floyd B.H., et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 2004, 199:1133-1142.